CA2204130A1 - Tachykinin antagonists - Google Patents
Tachykinin antagonistsInfo
- Publication number
- CA2204130A1 CA2204130A1 CA002204130A CA2204130A CA2204130A1 CA 2204130 A1 CA2204130 A1 CA 2204130A1 CA 002204130 A CA002204130 A CA 002204130A CA 2204130 A CA2204130 A CA 2204130A CA 2204130 A1 CA2204130 A1 CA 2204130A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- hydrogen
- compound
- formula
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
GB9425085.9 | 1994-12-13 | ||
GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
GB9426016.3 | 1994-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2204130A1 true CA2204130A1 (en) | 1996-06-20 |
Family
ID=26306161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002204130A Abandoned CA2204130A1 (en) | 1994-12-13 | 1995-12-12 | Tachykinin antagonists |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0797583A1 (sk) |
JP (1) | JPH10511935A (sk) |
AR (1) | AR001332A1 (sk) |
AU (1) | AU4343796A (sk) |
BR (1) | BR9509997A (sk) |
CA (1) | CA2204130A1 (sk) |
CO (1) | CO4700289A1 (sk) |
CZ (1) | CZ179097A3 (sk) |
FI (1) | FI971685A (sk) |
HU (1) | HUT77002A (sk) |
IL (1) | IL116323A0 (sk) |
NO (1) | NO972526L (sk) |
PE (1) | PE38997A1 (sk) |
PL (1) | PL320217A1 (sk) |
SK (1) | SK74697A3 (sk) |
TR (1) | TR199501568A2 (sk) |
WO (1) | WO1996018643A1 (sk) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998015277A2 (en) * | 1996-10-07 | 1998-04-16 | Merck Sharp & Dohme Limited | Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
CA2362290A1 (en) | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
GEP20125566B (en) | 2005-07-15 | 2012-07-10 | Amr Technology Inc | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
KR101591656B1 (ko) | 2007-01-10 | 2016-02-19 | 엠에스디 이탈리아 에스.알.엘. | 폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸 |
EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Msd株式会社 | インドールジオン誘導体 |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
CN102014631A (zh) | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | 酪氨酸激酶抑制剂 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
SG175420A1 (en) | 2009-05-12 | 2011-12-29 | Albany Molecular Res Inc | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
MX2012004377A (es) | 2009-10-14 | 2012-06-01 | Merck Sharp & Dohme | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos. |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
MX2015004041A (es) | 2012-09-28 | 2015-07-06 | Merck Sharp & Dohme | Compuestos novedosos que son inhibidores de erk. |
CA2892361A1 (en) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
JPH05186498A (ja) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
-
1995
- 1995-12-11 PE PE1995286859A patent/PE38997A1/es not_active Application Discontinuation
- 1995-12-11 IL IL11632395A patent/IL116323A0/xx unknown
- 1995-12-12 HU HU9701897A patent/HUT77002A/hu unknown
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/en not_active Application Discontinuation
- 1995-12-12 CA CA002204130A patent/CA2204130A1/en not_active Abandoned
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 JP JP8518261A patent/JPH10511935A/ja active Pending
- 1995-12-12 BR BR9509997A patent/BR9509997A/pt not_active Application Discontinuation
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/cs unknown
- 1995-12-12 PL PL95320217A patent/PL320217A1/xx unknown
- 1995-12-12 SK SK746-97A patent/SK74697A3/sk unknown
- 1995-12-12 EP EP95942131A patent/EP0797583A1/en not_active Withdrawn
- 1995-12-12 CO CO95058767A patent/CO4700289A1/es unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/xx unknown
- 1995-12-13 AR AR33458995A patent/AR001332A1/es unknown
-
1997
- 1997-04-18 FI FI971685A patent/FI971685A/fi not_active Application Discontinuation
- 1997-06-03 NO NO972526A patent/NO972526L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU4343796A (en) | 1996-07-03 |
IL116323A0 (en) | 1996-03-31 |
AR001332A1 (es) | 1997-10-22 |
EP0797583A1 (en) | 1997-10-01 |
MX9703957A (es) | 1997-09-30 |
HUT77002A (hu) | 1998-03-02 |
JPH10511935A (ja) | 1998-11-17 |
CO4700289A1 (es) | 1998-12-29 |
TR199501568A2 (tr) | 1996-07-21 |
BR9509997A (pt) | 1997-12-30 |
WO1996018643A1 (en) | 1996-06-20 |
CZ179097A3 (en) | 1997-10-15 |
FI971685A0 (fi) | 1997-04-18 |
SK74697A3 (en) | 1997-11-05 |
PE38997A1 (es) | 1997-10-02 |
FI971685A (fi) | 1997-08-13 |
NO972526D0 (no) | 1997-06-03 |
PL320217A1 (en) | 1997-09-15 |
NO972526L (no) | 1997-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2204130A1 (en) | Tachykinin antagonists | |
KR100637110B1 (ko) | 세포 유착 억제제 | |
US4668769A (en) | Oxa- and azahomocyclostatine polypeptides | |
US4599198A (en) | Intermediates in polypeptide synthesis | |
US5559128A (en) | 3-substituted piperidines promote release of growth hormone | |
AU726585B2 (en) | Biarylalkanoic acids as cell adhesion inhibitors | |
AU2001288285B2 (en) | Substituted piperidines as melanocortin receptor agonists | |
JP5368089B2 (ja) | Hcvインヒビター | |
SK5592003A3 (en) | Lactam compound to inhibit beta-amyloid peptide release or synthesis | |
JP3817256B2 (ja) | タキキニンアンタゴニスト | |
EP0644892A1 (en) | Inhibitors of angiotensin i chymase(s) including human heart chymase | |
HU193671B (en) | Process for producing benzazoninine derivatives and pharmaceutical compositions containing them as active agents | |
WO2008086053A1 (en) | Hcv inhibitors | |
EP0933379B1 (en) | Novel peptide derivatives having thiazolyl-alanine residue | |
SE447389B (sv) | Nya tripeptider, som inverkar pa det centrala nervsystemet | |
JP2002536434A (ja) | 5−ht1fアゴニスト | |
JP2003511447A (ja) | 置換ジアゼパン類 | |
US6407065B1 (en) | VLA-4 antagonists | |
US5714470A (en) | Orally-active elastase inhibitors | |
JPH01163164A (ja) | アミノ酸誘導体 | |
MXPA97003957A (en) | Antagonists of taquicin | |
CA3173702A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
HU203249B (en) | Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient | |
JPH03148248A (ja) | アミノ酸誘導体 | |
WO2001042192A2 (en) | Vla-4 integrin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |